, Volume 78, Issue 16, pp 1751–1755 | Cite as

Pyrotinib: First Global Approval

  • Hannah A. BlairEmail author
AdisInsight Report


Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Escriva-de-Romani S, Arumi M, Bellet M, et al. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018;39:80–8.CrossRefGoogle Scholar
  2. 2.
    Ponde N, Brandao M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20.CrossRefGoogle Scholar
  3. 3.
    Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51–61.CrossRefGoogle Scholar
  4. 4.
    De Leon J. China approves Hengrui breast cancer drug on phase II data; 2018. Accessed 25 Sep 2018.
  5. 5.
    Lovells H. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs; 2018. Accessed 3 Sept 2018.
  6. 6.
    State Food and Drug Administration. Pyrotinib maleate tablets: prescribing information; 2018. Accessed 25 Sep 2018.
  7. 7.
    Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105–12.CrossRefGoogle Scholar
  8. 8.
    Wang Y, Qin Z, Wang Q, et al. Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation [abstract no. e24281]. J Clin Oncol. 2018;36(Suppl 15).Google Scholar
  9. 9.
    Zhu Y, Li L, Zhang G, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1033–1034:117–27.CrossRefGoogle Scholar
  10. 10.
    Xu B, Ma F, Ouyang Q, et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab. [abstract no. PD3-08 plus poster]. Cancer Res. 2017;78(Suppl 4).Google Scholar
  11. 11.
    Ren S, Zhou C, Gao G, et al. Preliminary results of a phase II study about the efficacy and safety of pyrotinib in patients with HER2 mutant advanced NSCLC [abstract no. MA04.03]. J Thorac Oncol. 2017;12(Suppl 1):S359.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations